Oxford Drug Design has been awarded £1 ($1.2) million in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme from PACE (Pathways to Antimicrobial Clinical Efficacy). In the UK, there were over 1.8 million hospital admissions involving UTIs between 2018-19 and 2022-23, with the condition being responsible for around 236,000 deaths in 2019. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!